Transplantation-related characteristics of patients who underwent allogeneic transplantation for mm between 1989 and 2005
| Variables . | 1989-1994, n (%) . | 1995-2000, n (%) . | 2001-2005, n (%) . | P . |
|---|---|---|---|---|
| Conditioning regimen | < .001 | |||
| Myeloablative | 324 (95) | 279 (74) | 105 (22) | |
| Cy + TBI | 152 (44) | 99 (26) | 19 (4) | |
| Bu + Cy | 129 (38) | 94 (25) | 19 (4) | |
| TBI ≥ 500 cGY single or TBI ≥ 800 cGY fractions | 33 (10) | 65 (17) | 23 (5) | |
| Other regimens* | 10 (2) | 23 (6) | 45 (9) | |
| Nonmyeloablative/RIC | 14 (4) | 86 (23) | 344 (70) | |
| Low-dose TBI | 5 (1) | 12 (4) | 73 (15) | |
| LPAM ≤ 150 mg/m2 | 1 (< 1) | 27 (7) | 108 (22) | |
| Bu ≤ 9 mg/kg | 6 (2) | 21 (6) | 42 (9) | |
| Flud + Cy | 0 | 7 (2) | 41 (8) | |
| Flud +TBI = 200 cGY | 0 | 16 (4) | 79 (16) | |
| CBV | 2 (< 1) | 1 (< 1) | 0 | |
| Missing | 5 (1) | 11 (3) | 39 (8) | |
| Donor type | < .001 | |||
| HLA-identical | 316 (92) | 262 (70) | 322 (66) | |
| Other related | 11 (3) | 19 (5) | 9 (2) | |
| Unrelated | 16 (5) | 95 (25) | 157 (32) | |
| Graft type | < .001 | |||
| BM | 342 (99) | 196 (52) | 58 (12) | |
| PBSC | 1 (< 1) | 180 (48) | 430 (88) | |
| Donor age | .181 | |||
| < 30 y | 35 (10) | 46 (12) | 52 (11) | |
| 30-40 y | 96 (28) | 93 (25) | 114 (23) | |
| 40-50 y | 133 (39) | 124 (33) | 171 (35) | |
| ≥ 50 y | 70 (20) | 98 (26) | 139 (28) | |
| Missing | 9 (3) | 15 (4) | 12 (2) | |
| ATG use | 8 (2) | 47 (13) | 91 (19) | < .001 |
| GVHD prophylaxis | < .001 | |||
| T-cell depletion | 59 (17) | 80 (21) | 16 (3) | |
| FK506 + MTX + others | 2 (< 1) | 22 (6) | 74 (15) | |
| FK506 + others | 1 (< 1) | 19 (5) | 67 (14) | |
| CsA + MTX + others | 235 (69) | 177 (47) | 103 (21) | |
| CsA + others | 41 (12) | 70 (19) | 212 (43) | |
| Others | 5 (1) | 8 (2) | 16 (3) | |
| Planned maintenance therapy | < .001 | |||
| No | 294 (86) | 246 (65) | 226 (46) | |
| Yes | 35 (10) | 42 (11) | 99 (20) | |
| Missing | 14 (4) | 88 (23) | 163 (33) | |
| Median follow-up of survivors, mo (range) | 123 (3-204) | 86 (3-135) | 36 (3-81) | |
| Maximum grade of chronic GVHD† | .005 | |||
| No chronic GVHD | 228 (66) | 260 (69) | 288 (59) | |
| Limited | 52 (15) | 42 (11) | 67 (14) | |
| Extensive | 63 (18) | 74 (20) | 133 (27) | |
| Maximum overall severity of chronic GVHD‡ | < .001 | |||
| No chronic GVHD | 228 (66) | 260 (69) | 288 (59) | |
| Mild | 52 (15) | 40 (11) | 101 (21) | |
| Moderate | 36 (10) | 37 (10) | 62 (13) | |
| Severe | 22 (6) | 16 (4) | 30 (6) | |
| Unknown/missing | 5 (1) | 23 (6) | 7 (1) |
| Variables . | 1989-1994, n (%) . | 1995-2000, n (%) . | 2001-2005, n (%) . | P . |
|---|---|---|---|---|
| Conditioning regimen | < .001 | |||
| Myeloablative | 324 (95) | 279 (74) | 105 (22) | |
| Cy + TBI | 152 (44) | 99 (26) | 19 (4) | |
| Bu + Cy | 129 (38) | 94 (25) | 19 (4) | |
| TBI ≥ 500 cGY single or TBI ≥ 800 cGY fractions | 33 (10) | 65 (17) | 23 (5) | |
| Other regimens* | 10 (2) | 23 (6) | 45 (9) | |
| Nonmyeloablative/RIC | 14 (4) | 86 (23) | 344 (70) | |
| Low-dose TBI | 5 (1) | 12 (4) | 73 (15) | |
| LPAM ≤ 150 mg/m2 | 1 (< 1) | 27 (7) | 108 (22) | |
| Bu ≤ 9 mg/kg | 6 (2) | 21 (6) | 42 (9) | |
| Flud + Cy | 0 | 7 (2) | 41 (8) | |
| Flud +TBI = 200 cGY | 0 | 16 (4) | 79 (16) | |
| CBV | 2 (< 1) | 1 (< 1) | 0 | |
| Missing | 5 (1) | 11 (3) | 39 (8) | |
| Donor type | < .001 | |||
| HLA-identical | 316 (92) | 262 (70) | 322 (66) | |
| Other related | 11 (3) | 19 (5) | 9 (2) | |
| Unrelated | 16 (5) | 95 (25) | 157 (32) | |
| Graft type | < .001 | |||
| BM | 342 (99) | 196 (52) | 58 (12) | |
| PBSC | 1 (< 1) | 180 (48) | 430 (88) | |
| Donor age | .181 | |||
| < 30 y | 35 (10) | 46 (12) | 52 (11) | |
| 30-40 y | 96 (28) | 93 (25) | 114 (23) | |
| 40-50 y | 133 (39) | 124 (33) | 171 (35) | |
| ≥ 50 y | 70 (20) | 98 (26) | 139 (28) | |
| Missing | 9 (3) | 15 (4) | 12 (2) | |
| ATG use | 8 (2) | 47 (13) | 91 (19) | < .001 |
| GVHD prophylaxis | < .001 | |||
| T-cell depletion | 59 (17) | 80 (21) | 16 (3) | |
| FK506 + MTX + others | 2 (< 1) | 22 (6) | 74 (15) | |
| FK506 + others | 1 (< 1) | 19 (5) | 67 (14) | |
| CsA + MTX + others | 235 (69) | 177 (47) | 103 (21) | |
| CsA + others | 41 (12) | 70 (19) | 212 (43) | |
| Others | 5 (1) | 8 (2) | 16 (3) | |
| Planned maintenance therapy | < .001 | |||
| No | 294 (86) | 246 (65) | 226 (46) | |
| Yes | 35 (10) | 42 (11) | 99 (20) | |
| Missing | 14 (4) | 88 (23) | 163 (33) | |
| Median follow-up of survivors, mo (range) | 123 (3-204) | 86 (3-135) | 36 (3-81) | |
| Maximum grade of chronic GVHD† | .005 | |||
| No chronic GVHD | 228 (66) | 260 (69) | 288 (59) | |
| Limited | 52 (15) | 42 (11) | 67 (14) | |
| Extensive | 63 (18) | 74 (20) | 133 (27) | |
| Maximum overall severity of chronic GVHD‡ | < .001 | |||
| No chronic GVHD | 228 (66) | 260 (69) | 288 (59) | |
| Mild | 52 (15) | 40 (11) | 101 (21) | |
| Moderate | 36 (10) | 37 (10) | 62 (13) | |
| Severe | 22 (6) | 16 (4) | 30 (6) | |
| Unknown/missing | 5 (1) | 23 (6) | 7 (1) |
Cy indicates cyclophosphamide; TBI, total body irradiation; Bu, busulfan; low-dose TBI, < 500 cGy single fraction or > 800 cGy multiple fractions; LPAM, melphalan; Flud, fludarabine; CBV, cyclophosphamide + carmustine (BCNU) + etoposide (VP-16); PBSC, peripheral blood stem cells; ATG, antithymocyte globulin; FK506, tacrolimus; MTX, methotrexate; and CsA, cyclosporine.
Other regimens include Cy + VP16 + TBI, LPAM > 150 mg/m2, Bu > 9 mg/kg, or Bu + LPAM.
Limited versus extensive; P = .112.
Mild versus moderate versus severe; P = .53.